| Index | — | P/E | — | EPS (ttm) | -3.75 | Insider Own | 3.76% | Shs Outstand | 52.38M | Perf Week | -0.42% |
| Market Cap | 7.57B | Forward P/E | 37.10 | EPS next Y | 3.89 | Insider Trans | -10.96% | Shs Float | 44.18M | Perf Month | -20.67% |
| Enterprise Value | 7.46B | PEG | — | EPS next Q | -0.62 | Short Float | 7.04% | Perf Quarter | -31.56% | ||
| Income | -192.00M | P/S | 9.75 | EPS this Y | — | Short Ratio | 4.29 | Perf Half Y | -30.07% | ||
| Sales | 776.00M | P/B | 91.15 | EPS next Y | — | ROA | -25.17% | Short Interest | 3.11M | Perf YTD | -20.92% |
| Book/sh | 1.58 | P/C | 23.64 | EPS next 5Y | — | ROE | -255.60% | 52W High | 260.19 -44.49% | Perf Year | 8.33% |
| Cash/sh | 6.11 | P/FCF | — | EPS past 3/5Y | — | ROIC | -50.73% | 52W Low | 123.50 16.95% | Perf 3Y | 126.10% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 133.68% — | Gross Margin | 93.24% | Volatility | 4.63% 4.13% | Perf 5Y | 260.17% |
| Dividend TTM | — | EV/Sales | 9.62 | EPS Y/Y TTM | — | Oper. Margin | -24.28% | ATR (14) | 7.19 | Perf 10Y | 1875.79% |
| Dividend Ex-Date | — | Quick Ratio | 1.34 | Sales Y/Y TTM | 56.77% | Profit Margin | -24.68% | RSI (14) | 24.32 | Recom | 2.04 |
| Dividend Gr. 3/5Y | — | Current Ratio | 1.43 | EPS Q/Q | -7.61% | SMA20 | -8.49% | Beta | 0.85 | Target Price | 281.67 |
| Payout | 0.00% | Debt/Eq | 2.64 | Sales Q/Q | 45.33% | SMA50 | -21.83% | Rel Volume | 2.68 | Prev Close | 143.45 |
| Employees | 1,346 | LT Debt/Eq | 1.80 | Earnings | Nov 02 | SMA200 | -27.54% | Avg Volume | 778.97K | Price | 144.43 |
| IPO Date | Nov 19, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -10.98% -2.15% | Net Debt/EBITDA | — | Volume | 2,090,151 | Change | 0.68% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-26-26 | Reiterated | Piper Sandler | Overweight | $258 → $238 |
| Oct-08-26 | Reiterated | RBC Capital | Outperform | $297 → $295 |
| Sep-29-26 | Reiterated | Deutsche Bank | Buy | $280 → $267 |
| Sep-25-26 | Reiterated | Morgan Stanley | Equal Weight | $251 → $247 |
| Sep-23-26 | Reiterated | Truist Securities | Buy | $200 → $285 |
| Aug-12-26 | Reiterated | Mizuho | Outperform | $230 → $316 |
| Aug-11-26 | Reiterated | Needham | Buy | $267 → $268 |
| Aug-11-26 | Reiterated | Guggenheim | Buy | $260 → $275 |
| Aug-11-26 | Reiterated | RBC Capital | Outperform | $304 → $297 |
| Aug-11-26 | Reiterated | Morgan Stanley | Equal Weight | $242 → $251 |
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 776 | 638 | 386 | 271 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 53 | 47 | 33 | 26 | — | — | — | — | — | |
| Gross Profit | 724 | 591 | 352 | 245 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 712 | 571 | 411 | 323 | — | — | — | — | — | |
| Research and Development | 188 | 183 | 187 | 98 | — | — | — | — | — | |
| Other Operating Expense | 12 | 6 | 35 | 55 | — | — | — | — | — | |
| Operating Income | -188 | -169 | -281 | -232 | — | — | — | — | — | |
| Interest Expense | 5 | 7 | 7 | 6 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 2 | -8 | 0 | 0 | — | — | — | — | — | |
| Net Income Before Taxes | -191 | -184 | -287 | -238 | — | — | — | — | — | |
| Income Taxes | 0 | -1 | 0 | 1 | — | — | — | — | — | |
| Consolidated Net Income | -192 | -183 | -287 | -239 | — | — | — | — | — | |
| Net Income From Continuing Operations | -192 | -183 | -287 | -239 | — | — | — | — | — | |
| Net Income | -192 | -183 | -287 | -239 | — | — | — | — | — | |
| EPS (Recurring) | -3.75 | -3.68 | -5.99 | -5.27 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.75 | -3.68 | -5.99 | -5.27 | — | — | — | — | — | |
| EPS (Diluted) | -3.75 | -3.68 | -5.99 | -5.27 | — | — | — | — | — | |
| EBITDA | -177 | -168 | -273 | -225 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 9.68 | 14.31 | 10.52 | 13.22 | — | — | — | — | — | |
| Gross Margin | 93.30 | 92.63 | 91.19 | 90.41 | — | — | — | — | — | |
| Operating Margin | -24.23 | -26.49 | -72.80 | -85.61 | — | — | — | — | — | |
| Net Margin | -24.74 | -28.68 | -74.35 | -88.19 | — | — | — | — | — | |
| Shares Outstanding | 52 | 50 | 48 | 45 | — | — | — | — | — | |
| Market Capitalization | 7,510 | 9,132 | 4,061 | 3,582 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Jacobson Mark L. | Chief Operating Officer | Sep 03 '26 | Sale | 208.65 | 10,000 | 2,086,500 | 0 | Sep 03 |
| Jacobson Mark L. | Chief Operating Officer | Sep 03 '26 | Option Exercise | 12.95 | 10,000 | 129,500 | 10,000 | Sep 03 |
| TABUTEAU HERRIOT | Chief Executive Officer | Aug 06 '26 | Sale | 213.95 | 4,660 | 997,007 | 7,229 | Aug 07 |
| TABUTEAU HERRIOT | Chief Executive Officer | Aug 06 '26 | Option Exercise | 4.95 | 4,660 | 23,067 | 11,889 | Aug 07 |
| TABUTEAU HERRIOT | Chief Executive Officer | Aug 05 '26 | Sale | 212.01 | 45,004 | 9,541,298 | 7,229 | Aug 07 |
| TABUTEAU HERRIOT | Chief Executive Officer | Aug 05 '26 | Option Exercise | 4.95 | 45,004 | 222,770 | 52,233 | Aug 07 |
| TABUTEAU HERRIOT | Chief Executive Officer | Jul 01 '26 | Option Exercise | 4.95 | 49,666 | 245,847 | 56,895 | Jul 01 |
| TABUTEAU HERRIOT | Chief Executive Officer | Jul 01 '26 | Sale | 240.25 | 49,666 | 11,932,257 | 7,229 | Jul 01 |
| JEFFS ROGER | Director | Jun 11 '26 | Sale | 249.12 | 286 | 71,248 | 58,367 | Jun 11 |
| JEFFS ROGER | Director | Jun 10 '26 | Sale | 246.18 | 286 | 70,407 | 58,653 | Jun 11 |
| Mahony Susan | Director | Jun 10 '26 | Sale | 246.18 | 300 | 73,854 | 829 | Jun 10 |
| Coleman Mark | Director | Jun 10 '26 | Sale | 249.00 | 643 | 160,107 | 30,389 | Jun 10 |
| Mahony Susan | Director | Jun 09 '26 | Sale | 237.21 | 300 | 71,163 | 1,129 | Jun 10 |
| JEFFS ROGER | Director | Jun 08 '26 | Option Exercise | 0.00 | 1,429 | 0 | 58,939 | Jun 10 |
| Mahony Susan | Director | Jun 08 '26 | Option Exercise | 0.00 | 1,429 | 0 | 1,429 | Jun 10 |